Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad^{1

2

3}, Christopher McCabe⁴, Sham Mailankody⁵

Affiliations

¹ Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA.
³ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA.
⁴ Executive Director and CEO of the Institute of Health Economics, Edmonton, Canada.
⁵ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.

Free article

Vinay Prasad et al. Nat Rev Clin Oncol. 2018 Jul.

Free article

. 2018 Jul;15(7):399-400.

doi: 10.1038/s41571-018-0030-2.

Vinay Prasad^{1

2

3}, Christopher McCabe⁴, Sham Mailankody⁵

¹ Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA.
³ Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA.
⁴ Executive Director and CEO of the Institute of Health Economics, Edmonton, Canada.
⁵ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.

No abstract available

MeSH terms